Drug Combination Details
| General Information of the Combination (ID: C98749) | |||||
|---|---|---|---|---|---|
| Name | Bisdemethoxycurcumin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Healthy individual
[ICD-11: N.A.]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HK2 | CVCL_0302 | Healthy | Homo sapiens | ||
| HKC | CVCL_WZ51 | Healthy | Homo sapiens | |||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| In-vivo Model | Male Institute of Cancer Research (ICR) mice were used in this study. | |||||
| Experimental
Result(s) |
Bisdemethoxycurcumin attenuates cisplatin-induced renal injury through anti-apoptosis, anti-oxidant and anti-inflammatory. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CA916798 | Molecule Info | ||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. | |||||
